Continuous glucose monitoring for the routine care of type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 207 of the 209 references it cites were found in a registry or an index.
Abstract
Although continuous glucose monitoring (CGM) devices are now considered the standard of care for people with type 1 diabetes mellitus, the uptake among people with type 2 diabetes mellitus (T2DM) has been slower and is focused on those receiving intensive insulin therapy. However, increasing evidence now supports the inclusion of CGM in the routine care of people with T2DM who are on basal insulin-only regimens or are managed with other medications. Expanding CGM to these groups could minimize hypoglycaemia while allowing efficient adaptation and escalation of therapies. Increasing evidence from randomized controlled trials and observational studies indicates that CGM is of clinical value in people with T2DM on non-intensive treatment regimens. If further studies confirm this finding, CGM could soon become a part of routine care for T2DM. In this Perspective we explore the potential benefits of widening the application of CGM in T2DM, along with the challenges that must be overcome for the evidence-based benefits of this technology to be delivered for all people with T2DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ajjan et al. 54 and Fernando et al. 55 provide strong support for expanding CGM use in noninsulin‐treated adults living with T2DM, including a proposed framework for the use of CGM throughout the natural history of T2D.”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667 · cited 1×
“HbA 1c is the gold standard marker for the risk of diabetes mellitus complications 7,197 but does not provide information on the frequency of hypoglycaemia, short-term glucose variability, or daily and/or weekly glycaemia patterns.”
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 4×
“HbA 1c is the gold standard marker for the risk of diabetes mellitus complications 7,197 but does not provide information on the frequency of hypoglycaemia, short-term glucose variability, or daily and/or weekly glycaemia patterns.”
Influential10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“The majority of studies of CGM in T2DM have shown that the use of this technology reduces HbA 1c , which is an accepted marker of micro-vascular complications and long-term macrovascular disease 7,8,84 .”
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283 · cited 1×
“The estimated prevalence of diabetes mellitus among people aged >60 years is 22% and 19% in high-income and middle-income countries, respectively 139 .”
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 3×
“…the risk of hypo-glycaemia in T2DM and achieve a time below range in hypoglycaemia of 3.0 mmol/l (54 mg/dl) target of 1% of readings each day 40 , it is important that glycaemic variability, as measured by coefficient of variation over the observation period, remains 30% of the mean…”
InfluentialSelf-citationAhlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335 · cited 3×
“HCPs must understand better the heterogeneity of T2DM and the diversity of patient profiles 101,102 , as well as the growing pharmacy of treatment options.”
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 1×
“Continuous glucose monitoring (CGM) data provide accurate glycaemic metrics 198,199 such as time in range (TIR), a central indicator of glycaemic control 40 .”
Self-citationSevere hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471 · cited 1×
“This finding is not surprising given the association between hypoglycaemia and adverse outcomes, such as hospitalization or ambulance attendance 73,74 , which is likely to be modifiable with the use of CGM to improve awareness of impending low blood levels of glucose 75 .”
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Cited by
Chen, Y., Yang, Z., Liu, Y., Gue, Y. X., Zhong, Z., Chen, T., Wang, F., McDowell, G., Huang, B., & Lip, G. Y. H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02521-7 · Cited by 39
“Continuous glucose monitoring offers a more comprehensive approach, capturing real-time changes and providing better insight into glycemic variability [59].”
Layne, J. E., Jepson, L. H., Carite, A. M., Parkin, C. G., & Bergenstal, R. M. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0197 · Cited by 37
“19 As with glycemic targets, many patient factors may contribute to determining optimal CGM wear cadence and further research may support different recommendations based upon these factors.”
Wang, Y., Lu, J., Yu, J., Ni, J., Wang, M., Lu, W., Zhu, W. M., Guo, J., Bao, Y., & Zhou, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16143 · Cited by 30
Benhalima, K., Durnwald, C. P., Sweeting, A., Adams, D., Addala, A., Battelino, T., Bergenstal, R. M., Carlson, A. L., Donovan, L., Franco, D. R., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00335-3 · Cited by 37
Self-citationAlkabbani, W., CROMER, S. J., Kim, D. H., Paik, J. M., Bykov, K., Munshi, M. N., Wexler, D. J., & Patorno, E. (2025) · Diabetes Care · doi:10.2337/dca25-0006 · Cited by 32
Metadata
- Authors
- Ajjan, R. A., Battelino, T., Cos, X., Del Prato, S., Philips, J.-C., Meyer, L., Seufert, J., & Seidu, S.
- Affiliations
- University of Leeds (GB)
- University of Ljubljana (SI)
- Institut Universitari d'Investigació en Atenció Primària Jordi Gol (ES)
- University of Liège (BE)
- Hôpitaux Universitaires de Strasbourg (FR)
- University of Freiburg (DE)
- University of Leicester (GB)
- Corresponding author
- Seidu, Samuel
- ORCID
- Venue
- Nature Reviews Endocrinology
- Published
- 2024-04-08
- Volume
- 20
- Issue
- 7
- Pages
- 426-440
- ISSN
- 1759-5029 (ISSN-L)
- 1759-5037
- OpenAlex
- W4394579926
- Cited by
- 117
- References
- 209
- Citations by year
- 2026: 58 · 2025: 48 · 2024: 11
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- continuous glucose monitoring, type 2 diabetes, hypoglycemia prevention, treatment intensification, disease progression
- MeSH terms
- Continuous Glucose Monitoring, Blood Glucose, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin, Blood Glucose Self-Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Continuous glucose monitoring for the routine care of type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1038/s41574-024-00973-1
- The paper
- Ajjan, R. A., Battelino, T., Cos, X., Del Prato, S., Philips, J.-C., Meyer, L., Seufert, J., & Seidu, S. (2024). Continuous glucose monitoring for the routine care of type 2 diabetes mellitus. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-024-00973-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.